DE60137414D1 - Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese - Google Patents
Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-syntheseInfo
- Publication number
- DE60137414D1 DE60137414D1 DE60137414T DE60137414T DE60137414D1 DE 60137414 D1 DE60137414 D1 DE 60137414D1 DE 60137414 T DE60137414 T DE 60137414T DE 60137414 T DE60137414 T DE 60137414T DE 60137414 D1 DE60137414 D1 DE 60137414D1
- Authority
- DE
- Germany
- Prior art keywords
- arginase
- regeneration
- methods
- nervous system
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000011069 regeneration method Methods 0.000 title abstract 3
- 210000000653 nervous system Anatomy 0.000 title abstract 2
- 229920000768 polyamine Polymers 0.000 title abstract 2
- 230000008929 regeneration Effects 0.000 title abstract 2
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 102100021723 Arginase-1 Human genes 0.000 title 1
- 101710129000 Arginase-1 Proteins 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 4
- 102000004452 Arginase Human genes 0.000 abstract 3
- 108700024123 Arginases Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000001537 neural effect Effects 0.000 abstract 3
- 230000009689 neuronal regeneration Effects 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 210000002569 neuron Anatomy 0.000 abstract 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 abstract 2
- 102000006386 Myelin Proteins Human genes 0.000 abstract 1
- 108010083674 Myelin Proteins Proteins 0.000 abstract 1
- 239000005700 Putrescine Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 231100000858 damage to nervous tissue Toxicity 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000005012 myelin Anatomy 0.000 abstract 1
- 230000007514 neuronal growth Effects 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000000754 repressing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20230700P | 2000-05-05 | 2000-05-05 | |
| PCT/US2001/014364 WO2001085981A2 (en) | 2000-05-05 | 2001-05-04 | Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60137414D1 true DE60137414D1 (de) | 2009-03-05 |
Family
ID=22749330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60137414T Expired - Lifetime DE60137414D1 (de) | 2000-05-05 | 2001-05-04 | Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7741310B2 (de) |
| EP (1) | EP1278537B1 (de) |
| AT (1) | ATE420656T1 (de) |
| AU (2) | AU5945301A (de) |
| CA (1) | CA2408255A1 (de) |
| DE (1) | DE60137414D1 (de) |
| ES (1) | ES2322332T3 (de) |
| HK (1) | HK1054680A1 (de) |
| WO (1) | WO2001085981A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002343609B2 (en) | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| WO2003043616A2 (en) * | 2001-11-16 | 2003-05-30 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| US20050009847A1 (en) * | 2002-11-20 | 2005-01-13 | Goran Bertilsson | Compounds and methods for increasing neurogenesis |
| US8871999B2 (en) * | 2004-10-29 | 2014-10-28 | Board Of Trustees Of Michigan State University | Protection against herbivores |
| US20090111748A1 (en) * | 2005-07-21 | 2009-04-30 | Ellerby Lisa M | Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease |
| JP2009532369A (ja) | 2006-03-30 | 2009-09-10 | リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク | 分泌性白血球プロテアーゼインヒビターによる神経再生の刺激 |
| AU2008207287A1 (en) * | 2007-01-19 | 2008-07-24 | Howard Florey Institute Of Experimental Physiology And Medicine | Use of galanin in a method of treating neurodegenerative diseases or conditions |
| US9034299B2 (en) | 2007-08-03 | 2015-05-19 | Cornell University | ATF4 inhibitors and their use for neural protection, repair, regeneration, and plasticity |
| US20110016548A1 (en) * | 2009-07-16 | 2011-01-20 | University Of Southern California | Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems |
| US11268655B2 (en) | 2018-01-09 | 2022-03-08 | Cryoport, Inc. | Cryosphere |
| US20210340516A1 (en) * | 2020-04-29 | 2021-11-04 | Augusta University Research Institute, Inc. | Compositions containing arginase 1 for the treatment of neurovascular and retinal vascular disorders |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395612A (en) * | 1990-03-27 | 1995-03-07 | Cornell Research Foundation, Inc. | Method for treating systemic hypotension caused by sepsis or cytokine using arginase in combination with an α1 adrenergic agonist |
| AU2300092A (en) * | 1991-07-03 | 1993-02-11 | Nathan E. Scott | Prostaglandin e2 treatment of impotence |
| EP0593516B1 (de) | 1991-07-10 | 2001-07-11 | Regeneron Pharmaceuticals, Inc. | Verfahren zur behandlung von erkrankungen motorischer neuronen durch mitglieder der bdnf/nt-3/ngf-familie |
| FR2717496B1 (fr) * | 1994-03-18 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
| US6096716A (en) * | 1994-12-12 | 2000-08-01 | The Board Of Regents, The University Of Texas System | Liposome-mediated transfection of central nervous system cells |
| DE69633336T2 (de) * | 1995-06-27 | 2005-09-22 | Research Foundation Of Cuny | Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält |
| US5731284A (en) | 1995-09-28 | 1998-03-24 | Amgen Inc. | Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product |
| WO1997030167A1 (en) | 1996-02-13 | 1997-08-21 | The Trustees Of The University Of Pennsylvania | Method of treating liver disorders |
| US6222022B1 (en) | 1996-03-14 | 2001-04-24 | Washington University | Persephin and related growth factors |
| US5741778A (en) | 1996-03-19 | 1998-04-21 | Amgen Inc. | Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product |
| US5990168A (en) | 1996-04-18 | 1999-11-23 | Alberta Cancer Board | Methods and compositions for the treatment of ataxia telangiectasia |
| AU2677797A (en) | 1996-04-25 | 1997-11-12 | Genetic Therapy, Inc. | Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor |
| EP1049660A1 (de) * | 1997-10-10 | 2000-11-08 | The Trustees Of The University Of Pennsylvania | Gemische und verfahren zur hemmung der aktivität der arginase |
| WO1999043345A1 (en) * | 1998-02-26 | 1999-09-02 | Eisai Co., Ltd. | Amino acid degrading enzymes modulate cell death |
| US6284540B1 (en) | 1998-09-29 | 2001-09-04 | Washington University | Artemin, a novel neurotrophic factor |
| US6708712B2 (en) * | 2001-10-04 | 2004-03-23 | Illinois Tool Works Inc. | Pressure regulator utilizing a disc spring |
| AU2002343609B2 (en) * | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| JP2005532997A (ja) * | 2002-03-01 | 2005-11-04 | チルドレンズ ホスピタル メディカル センター | 喘息またはアレルギーの処置 |
-
2001
- 2001-05-04 CA CA002408255A patent/CA2408255A1/en not_active Abandoned
- 2001-05-04 US US10/275,513 patent/US7741310B2/en not_active Expired - Fee Related
- 2001-05-04 EP EP01932977A patent/EP1278537B1/de not_active Expired - Lifetime
- 2001-05-04 AU AU5945301A patent/AU5945301A/xx active Pending
- 2001-05-04 AU AU2001259453A patent/AU2001259453B2/en not_active Ceased
- 2001-05-04 DE DE60137414T patent/DE60137414D1/de not_active Expired - Lifetime
- 2001-05-04 ES ES01932977T patent/ES2322332T3/es not_active Expired - Lifetime
- 2001-05-04 HK HK03105409.1A patent/HK1054680A1/zh unknown
- 2001-05-04 WO PCT/US2001/014364 patent/WO2001085981A2/en not_active Ceased
- 2001-05-04 AT AT01932977T patent/ATE420656T1/de not_active IP Right Cessation
-
2009
- 2009-11-05 US US12/613,310 patent/US8673594B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2408255A1 (en) | 2001-11-15 |
| AU2001259453B2 (en) | 2006-08-31 |
| HK1054680A1 (zh) | 2003-12-12 |
| ES2322332T3 (es) | 2009-06-19 |
| US8673594B2 (en) | 2014-03-18 |
| WO2001085981A2 (en) | 2001-11-15 |
| EP1278537A2 (de) | 2003-01-29 |
| ATE420656T1 (de) | 2009-01-15 |
| AU5945301A (en) | 2001-11-20 |
| WO2001085981A3 (en) | 2002-03-14 |
| EP1278537B1 (de) | 2009-01-14 |
| US7741310B2 (en) | 2010-06-22 |
| US20030215428A1 (en) | 2003-11-20 |
| US20100216710A1 (en) | 2010-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE275415T1 (de) | Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält | |
| WO2002045749A3 (en) | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 | |
| CY1123341T1 (el) | Μη επιλεκτικο καναλι κατιοντων στα νευρωνικα κυτταρα και ενωσεις που μπλοκαρουν το καναλι για χρηση στη θεραπευτικη αντιμετωπιση της εγκεφαλικης εξοιδησης | |
| DE60137414D1 (de) | Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese | |
| ATE323482T1 (de) | Verwendung von p38 mapk inhibitoren in der behandlung von augenkrankheiten | |
| DE69942702D1 (de) | Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen | |
| DE60335244D1 (de) | Behandlung von verletzungen des zentralen nervensystems | |
| WO2004096245A3 (en) | Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration | |
| WO2002036829A3 (en) | Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries | |
| ATE254172T1 (de) | Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase | |
| WO2004026107A3 (en) | Kits and methods for assessing skin health | |
| DK1373502T3 (da) | Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf | |
| WO2005061002A3 (en) | Composition and methods for modulating cns activity | |
| WO2001042784A3 (en) | Methods for screening compounds active on neurons | |
| PT1255734E (pt) | Derivados de isatina com actividade neurotrofica | |
| WO2004016751A3 (en) | Methods of treating neurodegenerative diseases | |
| DE69620027D1 (de) | Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs | |
| WO2007035722A3 (en) | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | |
| WO2003030836A3 (en) | Neuronal regeneration | |
| EP1469730A4 (de) | Verfahren und zusammensetzungen zur behandlung der parkinson-krankheit | |
| GEP20063859B (en) | Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses | |
| WO2002017891A3 (de) | Verfahren zur diagnostik von neuronalen erkrankungen sowie zur behandlung der defizienten primären hämostase | |
| ATE311901T1 (de) | Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten | |
| WO2024081592A3 (en) | Constructs relating to genetic disorders | |
| WO2004080448A3 (de) | Verwendung von nep-assoziierten molekülen zur behandlung von nichtimmunogenen-nichthypertensiven zivilisationskrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |